drugset / Trial / NCT00850785
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
Phase 1
Completed
6 enrolled
Providence Health & Services
National Cancer Institute (NCI) · collabThe Wayne D. Kuni and Joan E. Kuni Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot single institution study of DRibble vaccination + GM-CSF in patients with stage IIIB or IV NSCLC who have undergone 0-1 chemotherapy regimens for metastatic disease. The primary objective of this trial is to evaluate immune responses induced by autologous DRibble vaccine in vivo and in vitro and against autologous and allogeneic lung cancer cells.
Timeline
- Start
- 2009-01
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DRibble vaccine | Vaccine | 5e+06 cells | Intrathecal |
| Subject | DRibble vaccine | Vaccine | 2e+07 cells | Intrathecal |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Background | sargramostim | Protein / enzyme biologic | 50 ug | Subcutaneous |